Arbovirus Testing Market Size & Growth Forecast 2027–2036, By Segments (Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Arbovirus Testing Market size was estimated at USD 1.2 billion in 2026 and is projected to grow at a 4.28% CAGR from 2027 to 2036, exceeding USD 1.82 billion by 2036. The industry revenue for 2027 is calculated at USD 1.24 billion.
Get more details on this report
Request Free Sample ReportArbovirus Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 44.10% share in 2026, supported by established diagnostic laboratory networks, advanced healthcare infrastructure, and routine infectious disease surveillance using molecular and serological testing.
- Asia Pacific is projected to grow at a 6.55% CAGR as expanding public health surveillance, recurring mosquito-borne disease outbreaks, and greater demand for early diagnosis increase testing adoption.
Segment Momentum
- ELISA-based tests lead with a 51.62% share due to scalable, cost-effective screening and established use in routine diagnostics, enabling efficient processing of large sample volumes in clinical laboratories.
- RT-PCR tests are the fastest-growing segment as demand increases for precise molecular detection, offering higher diagnostic confidence and improved ability to identify arboviral infections early.
Market Expansion Drivers
- Rising dengue and Zika incidence driving demand for rapid outbreak diagnostics and surveillance.
- Expanding use of ELISA-based diagnostic testing in clinical laboratories for routine screening.
- WHO and global health programs strengthening diagnostic infrastructure and NTD testing standardization initiatives.
Leading Market Participants
- Leading players in the arbovirus testing market include Abbott Laboratories (United States), Thermo Fisher Scientific Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (United States), EUROIMMUN Medizinische Labordiagnostika AG (Germany), Merck KGaA (Germany), Agilent Technologies, Inc. (United States), bioMérieux SA (France).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.2 billion
- 2027 Estimated Market Size: USD 1.24 billion.
- Projected Market Size: USD 1.82 billion by 2036
- Growth Forecast: 4.28% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: ELISA-based Tests (Type) | Diagnostic Laboratories (End Use)
- Emerging Opportunity Segment: RT-PCR Based Tests (Type) | Research Centers (End Use)
Market Growth Drivers and Industry Trends
Rising dengue and Zika incidence driving demand for rapid outbreak diagnostics and surveillance
The arbovirus testing market growth is being supported by the increasing incidence of dengue and zika infections, which creates a stronger need for timely diagnosis during outbreaks. Rapid and reliable testing enables healthcare systems to identify infected individuals earlier, support clinical decision-making, and improve the monitoring of transmission patterns across affected communities. During periods of heightened disease activity, diagnostic capabilities are particularly important for distinguishing arboviral infections from other illnesses with overlapping symptoms, while surveillance programs depend on consistent testing to track emerging hotspots and changes in transmission intensity. The need for faster outbreak response also encourages healthcare facilities and public health authorities to strengthen access to diagnostic tools that can be deployed across hospitals, laboratories, and community-based testing settings.
Expanding use of ELISA-based diagnostic testing in clinical laboratories for routine screening
Routine laboratory screening is increasing the role of ELISA-based methods within the arbovirus testing market, particularly because these assays can support systematic detection of antibodies or viral markers in clinical testing workflows. Clinical laboratories can incorporate ELISA testing into established diagnostic processes for patients presenting with symptoms associated with arboviral infections, as well as for screening purposes when exposure or epidemiological conditions warrant investigation. The ability to process multiple samples within laboratory settings makes ELISA suitable for organized testing programs, while its application across different arboviral infections supports broader diagnostic coverage. Growing attention to consistent laboratory-based screening is also encouraging healthcare providers to maintain testing capacity for both individual diagnosis and wider disease surveillance activities.
WHO and global health programs strengthening diagnostic infrastructure and NTD testing standardization initiatives
Global health initiatives are contributing to the arbovirus testing market by promoting stronger diagnostic infrastructure and greater consistency in testing practices across regions where vector-borne diseases remain a significant public health concern. Programs associated with the WHO and broader neglected tropical disease efforts can support improvements in laboratory capacity, diagnostic access, quality assurance, and standardized testing approaches, helping healthcare systems detect and monitor infections more effectively. Standardization is particularly important where differences in laboratory capabilities can affect the reliability and comparability of diagnostic results, while infrastructure development enables testing services to reach settings with limited access to specialized facilities. Such initiatives can also encourage the integration of arbovirus diagnostics into broader disease surveillance and public health response frameworks.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of arbovirus infections | 1.80% | Short term (≤ 2 yrs) | North America, Europe | Medium | Fast |
| Adoption of advanced diagnostic testing | 2.00% | Medium term (2–5 yrs) | North America, Asia Pacific | Low | Moderate |
| Expansion of healthcare and lab infrastructure in emerging markets | 2.00% | Long term (5+ yrs) | Asia Pacific, Latin America | Low | Slow |
| Rising dengue and Zika incidence driving demand for rapid outbreak diagnostics and surveillance | 2.10% | High | Asia Pacific, Latin America | High | Near Term |
| Expanding use of ELISA-based diagnostic testing in clinical laboratories for routine screening | 1.90% | Moderate | North America | High | Near Term |
| WHO and global health programs strengthening diagnostic infrastructure and NTD testing standardization initiatives | 1.70% | High | Africa, Asia Pacific | Medium | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America held the largest share of the arbovirus testing market at 44.10% in 2026, supported by established infectious disease surveillance systems, advanced diagnostic infrastructure, and strong demand for rapid detection of mosquito- and tick-borne viral infections. The region benefits from well-developed laboratory networks and widespread access to molecular and immunological testing technologies, enabling healthcare providers and public health authorities to identify infections and monitor transmission patterns effectively. Increasing awareness of vector-borne disease risks, preparedness for seasonal outbreaks, and continued investment in public health surveillance further reinforce testing demand. Integration of diagnostic capabilities into broader disease-monitoring programs also supports the region's strong market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing regional market, driven by favorable climatic conditions for vector proliferation, expanding healthcare infrastructure, and the increasing burden of mosquito-borne diseases in several countries. Urbanization and changing environmental conditions can contribute to shifting patterns of vector activity, creating greater requirements for timely and reliable diagnostic testing. Improvements in laboratory capacity, wider access to molecular diagnostics, and strengthening public health surveillance are supporting adoption across emerging healthcare systems. Growing government emphasis on infectious disease preparedness and increasing awareness among healthcare professionals are also encouraging earlier diagnosis and more systematic monitoring of arboviral infections.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
Germany 🇩🇪
Diagnostic Preparedness ProgramsGermany is strengthening arbovirus testing capabilities through improved laboratory preparedness and vector-borne disease monitoring initiatives. The market prioritizes accurate diagnostic tools that support timely identification of imported and locally transmitted infections.
France 🇫🇷
Integrated Disease DetectionFrance maintains active interest in arbovirus diagnostics due to ongoing monitoring of mosquito-borne disease risks in metropolitan and overseas territories. Diagnostic providers are focusing on testing solutions that enable efficient surveillance and outbreak containment strategies.
Italy 🇮🇹
Seasonal Surveillance CapacityItaly is expanding arbovirus testing capabilities to support seasonal monitoring and early identification of vector-borne infections. Public health authorities and laboratories are increasingly adopting advanced diagnostic technologies to improve response coordination and disease tracking.
Japan 🇯🇵
Vector Monitoring InitiativesJapan places emphasis on surveillance and diagnostic readiness for mosquito-borne diseases, particularly in densely populated regions. Healthcare institutions are increasingly adopting sensitive testing methods that facilitate early detection and outbreak management.
South Korea 🇰🇷
Rapid Response DiagnosticsSouth Korea is enhancing arbovirus testing infrastructure to support faster identification of vector-borne infections and strengthen public health response systems. The market is seeing growing adoption of molecular assays and integrated disease surveillance programs.
United States 🇺🇸
Public Health SurveillanceThe U.S. arbovirus testing market is shaped by increasing surveillance efforts and the need for rapid diagnostics during seasonal outbreaks. Laboratories and healthcare providers in the U.S. are expanding molecular testing capabilities to improve detection and epidemiological monitoring.
Arbovirus Testing Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: ELISA-based Tests (Largest Segment) vs RT-PCR Based Tests (Fastest-Growing Segment)
In the arbovirus testing market, ELISA-based tests held the largest share at 51.62% in 2026, supported by their established role in serological detection and their suitability for routine laboratory testing. These assays enable the identification of antibodies associated with arboviral infections and can be incorporated into established diagnostic workflows. Their relatively accessible testing procedures, compatibility with laboratory infrastructure, and usefulness in surveillance programs contribute to sustained demand, particularly where large numbers of samples require systematic screening.
RT-PCR based tests are advancing as the fastest-growing segment because of their ability to provide sensitive and specific detection of viral genetic material, particularly during the early stages of infection. The growing need for rapid and reliable confirmation of arboviral infections is encouraging greater adoption of molecular diagnostic approaches. Improvements in molecular testing workflows, expanding laboratory capabilities, and increased emphasis on early pathogen identification are further supporting the use of RT-PCR based tests in clinical and public health settings.
End Use Segment Analysis: Diagnostic Laboratories (Largest Segment) vs Research Centers (Fastest-Growing Segment)
Diagnostic laboratories represented the largest share of the arbovirus testing market in 2026, reflecting their central role in routine clinical diagnosis, confirmatory testing, and disease surveillance. These facilities require reliable testing methods to support physicians and public health programs in identifying arboviral infections and distinguishing them from other diseases with overlapping symptoms. Expanding diagnostic capabilities and the continued need for standardized laboratory testing are sustaining demand from this end-use group.
Research centers are expected to record the fastest growth as arbovirus research increasingly focuses on disease surveillance, pathogen characterization, diagnostic development, and evaluation of emerging testing technologies. Greater attention to outbreak preparedness and the evolution of mosquito- and tick-borne diseases is encouraging research institutions to strengthen testing capabilities. The increasing use of advanced molecular and immunological methods in translational research is also broadening the role of research centers in arbovirus testing.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | ELISA-based Tests, RT-PCR Based Tests, Others | ELISA-based Tests | RT-PCR Based Tests |
| End Use | Diagnostic Laboratories, Hospitals, Research Centers, Others | Diagnostic Laboratories | Research Centers |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Key companies in the arbovirus testing market:
1. Abbott Laboratories (United States)
2. Thermo Fisher Scientific Inc. (United States)
3. F. Hoffmann-La Roche Ltd (Switzerland)
4. Siemens Healthineers AG (Germany)
5. QIAGEN N.V. (Netherlands)
6. Bio-Rad Laboratories Inc. (United States)
7. EUROIMMUN Medizinische Labordiagnostika AG (Germany)
8. Merck KGaA (Germany)
9. Agilent Technologies Inc. (United States)
10. bioMérieux SA (France)
The arbovirus testing market is advancing through improved diagnostic accuracy and faster detection technologies. Enhanced testing platforms are enabling quicker outbreak identification and response. New diagnostic solution launches are improving laboratory efficiency and reliability. Collaborative research initiatives are further strengthening detection capabilities, supporting the arbovirus testing market in addressing evolving infectious disease challenges.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| EUROIMMUN Medizinische Labordiagnostika AG (Germany) | |||||||
| Merck KGaA (Germany) | |||||||
| Agilent Technologies Inc. (United States) | |||||||
| bioMérieux SA (France). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| FDA | Jan-25 | The U.S. FDA issued streamlined regulatory guidance for emerging pathogen in vitro diagnostic approvals, reducing barriers for arbovirus testing solutions. The policy is expected to accelerate commercialization timelines for new diagnostic technologies and expand market entry opportunities for RT-PCR and other molecular test platforms. |
| FDA | Nov-23 | The FDA approved IXCHIQ, the first chikungunya vaccine in the United States, influencing arbovirus testing demand by increasing pre- and post-vaccination diagnostic requirements. The approval contributes to evolving clinical workflows for arbovirus surveillance and reinforces demand for confirmatory and differential diagnostic testing solutions. |
| Astellas Pharma Inc. | May-23 | Astellas Pharma Inc. committed to supporting Phase III of the Global Health Innovative Technology Fund (GHIT Fund), collaborating with cross-sector funding partners to advance global health innovation. The initiative indirectly supports development pathways for infectious disease diagnostics, reinforcing broader ecosystem funding for arbovirus-related testing and surveillance innovation. |
| Mylab | Jul-22 | Mylab launched the PathoDetect Extended Monsoon Fever Panel, a multiplex RT-PCR assay designed to detect multiple arboviruses and related infections including dengue, zika, and malaria. The compact test system delivers results within approximately two hours and supports scaled diagnostic capacity for outbreak surveillance and infectious disease management. |
| Anitoa Systems | May-22 | Anitoa Systems introduced a portable RT-PCR molecular diagnostic platform for dengue detection using the Maverick qPCR instrument and lyophilized multiplex RT-PCR reagents. The solution enables rapid identification of dengue infections and expands portable molecular testing capabilities, strengthening point-of-care arbovirus diagnostic accessibility. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Arbovirus Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Target Disease | Dengue, Chikungunya, Zika, West Nile Virus, Yellow Fever & Other Arboviruses |
| Sample Type | Blood & Serum, Plasma, Urine, Cerebrospinal Fluid, Other Clinical Samples |
| Testing Purpose | Clinical Diagnosis, Epidemiological Surveillance, Blood Screening, Research & Public Health Monitoring |
Arbovirus Testing Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Emerging Disease Surveillance Landscape |
|
| Public Health Preparedness and Testing Infrastructure |
|
| Funding and Procurement Opportunity Analysis |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How much is the arbovirus testing market worth?
What is the anticipated CAGR of the arbovirus testing industry?
How is the shift toward molecular confirmation reshaping diagnostic workflows in the arbovirus testing market?
What is driving the expansion of surveillance-driven testing demand in arbovirus diagnostics?
Why do ELISA-based tests dominate the arbovirus testing market?
What is driving growth in RT-PCR based testing?
Why does North America lead the arbovirus testing market?
What is fueling arbovirus testing market growth in Asia Pacific?
What are the key competitors in the arbovirus testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook